This is a Phase 3 randomized, parallel-group, double-blind, placebo-controlled trial (Blinded
Treatment Period) followed by an Open-Label Extension Period intended to evaluate the
efficacy and safety of oral PRN1008 in moderate to severe pemphigus. After completing the
Open-Label Extension Period, eligible patients may continue in a Long Term Extension Period
of 48 weeks.
This is a Phase 3 randomized, parallel-group, double-blind, placebo-controlled trial (Blinded
Treatment Period) followed by an Open-Label Extension Period intended to evaluate the
efficacy and safety of oral PRN1008 in moderate to severe pemphigus. After completing the
Open-Label Extension Period, eligible patients may continue in a Long Term Extension Period
of 48 weeks.
Open Label Two-Arm Study to Evaluate Rilzabrutinib (PRN1008) in IgG4-Related Disease Patients
Recruiting
Massachusetts General Hospital
Phase 2
PRN1008-017 is a Phase 2a, multi-center, open-label, two-arm study of approximately 25
patients with active IgG4-related disease (IgG4-RD). The two arms include (1) Experimental:
PRN1008 with glucocorticoids and (2) Active Comparator: glucocorticoids only.
Open Label Two-Arm Study to Evaluate Rilzabrutinib (PRN1008) in IgG4-Related Disease Patients
Recruiting
Principia Biopharma Inc.
Phase 2
PRN1008-017 is a Phase 2a, multi-center, open-label, two-arm study of approximately 25
patients with active IgG4-related disease (IgG4-RD). The two arms include (1) Experimental:
PRN1008 with glucocorticoids and (2) Active Comparator: glucocorticoids only.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
